FOLD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amicus Therapeutics Inc (FOLD) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive momentum, has no strong proprietary trading signals, and faces challenges such as declining net income and EPS. Additionally, analysts have downgraded the stock, and there are no recent positive catalysts or significant trading trends to support a buy decision.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 47.526, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the price is stagnant with no clear upward trend. Support and resistance levels are tightly clustered, suggesting limited price movement.
NULL identified. No recent news or significant trading trends. Hedge funds and insiders are neutral.
Jefferies downgraded the stock to Hold from Buy with a reduced price target of $14.50, citing limited takeover interest. Financial performance shows a significant decline in net income (-88.53% YoY) and EPS (-80.00% YoY). Stock trend analysis predicts a potential decline of -1.18% in the next day, -1.83% in the next week, and -5.83% in the next month.
In Q4 2025, revenue increased by 23.72% YoY to $185.2M, but net income dropped by 88.53% YoY to $1.69M. EPS fell by 80.00% YoY to $0.01, and gross margin decreased by 4.61% YoY to 84.64%.
Jefferies downgraded the stock to Hold from Buy with a reduced price target of $14.50, down from $16. Analysts do not expect additional takeover bids for the company.
